Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of angiotensin II injection versus placebo in refractory distributive shock in Chinese adults
CTR20240761Phase 3Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of Angiotensin II in Vasoplegia, sponsored by Nanjing Shunxin Pharmaceutical. Started Jul 2024; status: completed.
02
Drugs
Angiotensin II
03
Conditions
Vasoplegia
Beyond the preview
Go deeper on CTR20240761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240761.